Search Results - rolf+swenson

8 Results

Sort By:

High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis

This technology includes a peptide containing alternating Alanine and Lys(DOTA-Gd) residues can be used to increase the MRI relaxivity of a peptide. The low molecular weight construct can be appended to proteins, antibodies and peptides to increase MRI signals. This approach offers advantages over previous dendrimeric constructs. The increased MRI signal...

Published: 8/12/2024 | Inventor(s): Rolf Swenson, Alan Koretsky, Nikorn Pothayee, Deepak Sail

Keywords(s):

Category(s): Application > Diagnostics, Application > Medical Devices, Application > Research Materials, Collaboration Sought > Licensing

Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease

This technology includes a new method to prepare very long chain fatty acids (VLCFA), which does not use the previously reported toxic mercury amalgam, for use as nutritional supplements, and as therapeutics for various diseases. The key coupling step involves an organocopper mediated coupling of the Grignard regent derived from the bromo alkyl tetraene...

Published: 9/11/2024 | Inventor(s): Rolf Swenson, Zhen-Dan Shi, Zhihong Yang, Alan Remaley

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing

Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging

This technology includes 1-13C-ketoglutarate which can be used for imaging the conversion to hydroxyglutarate (HG) or Gln in cancer cells with an IDH1 mutations by hyperpolarized MRI. The ability to detect the status of IDH1 mutations is clinically prognostic for multiple cancers. These exciting observations are limited by two factors, the major one...

Published: 8/12/2024 | Inventor(s): Rolf Swenson, Deepak Sail

Keywords(s):

Category(s): Application > Diagnostics, Application > Software / Apps, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, ResearchProducts > Research Equipment, TherapeuticArea > Oncology

Real-time Monitoring of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine as a Diagnostic and Disease Monitoring Tool

This technology includes synthesized demonstrated [1-13C] NAC as a promising novel probe for hyperpolarized 13C MRI methodologies which could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases. N-acetyl cysteine (NAC) is a widely used therapeutic and involved to stimulate glutathione synthesis. Glutathione...

Published: 8/12/2024 | Inventor(s): Murali Cherukuri, Rolf Swenson, Kazutoshi Yamamoto, Ana Opina

Keywords(s):

Category(s): Application > Diagnostics, Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Neurology, TherapeuticArea > Oncology

A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer

This technology includes a new chemical scaffold (with lead compound XL5) against hRpn13 that induces apoptosis, which may have clinical efficacy against cancer. The structure of XL5-conjugated hRpn13 guided the design of XL5-PROTAC degrader compounds that exhibit greater efficacy than previous hRpn13-targeting compounds, as evaluated by selectivity...

Published: 8/12/2024 | Inventor(s): Venkatareddy Sabbasani, Kylie Walters, Xiuxiu Lu, Nadya Tarasova, Rolf Swenson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression

This technology includes the use of LZK and DLK inhibitors to be used for the treatment of head and neck squamous cell carcinoma (HNSCC) or lung squamous cell carcinoma (LSCC). Specifically, we demonstrate that inhibitors that can be repurposed to target LZK suppresses LZK kinase-dependent stabilization of MYC and activation of the PI3K/AKT pathway....

Published: 8/12/2024 | Inventor(s): John Brognard, Rolf Swenson, Amy Funk, Carolyn Hitko, Katherine Nyswaner

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

PIM-Targeted PROTACs

Abstract: Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers – including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical...

Published: 4/8/2024 | Inventor(s): John Brognard, Rolf Swenson, Pedro Torres-Ayuso, Venkatareddy Sabbasani, Dawid Mehlich, Noel Warfel

Keywords(s): anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Enhanced Functionalization of Carbon Nanoparticles for Biomedical Applications

The invention pertains to methods of increasing the density of carboxylic acids on the surface of a carbon nanoparticle that can be functionalized with biologically relevant molecules, such as antibodies or peptides, for biomedical applications. Advantageously, the method could increase functionalization of a nanoparticle by at least about 1x107 functional...

Published: 7/25/2024 | Inventor(s): Chandrasekhar Mushti, Ganesh Shenoy, Rolf Swenson, Keir Neuman

Keywords(s): AG1XXX, CARBOXYLIC, fluorescent, MXXXXX, Nanodiamonds, nanotechnology, PXXXXX, WMXXXX, XGXXXX, YAXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Consumer Products, Application > Research Materials, Application > Diagnostics